Trade Name
(Generic Name)
|
Indication(s)
|
Company
|
Date Approved
|
|
ADCETRIS (brentuximab
vedotin)
|
Hodgkin Lymphoma, Systemic
Anaplastic Large Cell Lymphoma
|
Seattle Genetics
|
|
|
YERVOY (ipilimumab)
|
Late-Stage
Metastatic Melanoma
|
Bristol-Myers Squibb
|
|
|
BENLYSTA (belimumab)
|
Systemic Lupus Erythematosus
|
Human Genome
Sciences/
GlaxoSmithKline
|
|
|
XGEVA (denosumab)
|
Prevention of
Cancer-Related Bone Injury
|
Amgen
|
|
|
PROLIA (denosumab)
|
Osteoporosis
|
Amgen
|
|
|
ACTEMRA
(tocilizumab)
|
Rheumatoid Arthritis
|
Genentech
|
|
|
ARZERRA (ofatumumab)
|
Chronic Lymphocytic
Leukemia
|
GlaxoSmithKline
|
|
|
STELARA
(ustekinumab)
|
Psoriasis
|
Johnson &
Johnson
|
|
|
ILARIS (canakinumab)
|
Cryopyrin-Associated
Periodic Syndrome (CAPS)
|
Novartis
|
|
|
SIMPONI (golimumab)
|
Psoriatic Arthritis,
Rheumatoid Arthritis
|
Johnson &
Johnson
|
|
|
CIMZIA (certolizumab
pegol)
|
Crohn’s Disease
|
UCB
|
|
|
SOLIRIS (eculizumab)
|
Paroxysmal Nocturnal
Hemoglobinuria (PNH)
|
Alexion
Pharmaceuticals
|
|
|
VECTIBIX
(panitumumab)
|
Metastatic
Colorectal Cancer
|
Amgen
|
|
|
LUCENTIS
(ranibizumab)
|
Age-Related Macular
Degeneration
|
Genentech
|
|
|
TYSABRI
(natalizumab)
|
Relapsing Multiple
Sclerosis
|
Biogen Idec
|
|
|
AVASTIN
(bevacizumab)
|
Breast, Colorectal,
Lung, Renal Cell Cancers
|
Genentech
|
|
|
ERBITUX (cetuximab)
|
Colorectal Cancer
|
Bristol-Myers Squibb
|
|
|
RAPTIVA*
(efalizumab)
|
Plaque Psoriasis
|
Genentech
|
|
|
BEXXAR (tositumomab
iodine)
|
Non-Hodgkin’s
Lymphoma
|
GlaxoSmithKline
|
|
|
XOLAIR (omalizumab)
|
Allergy-Related
Asthma
|
Genentech &
Novartis
|
|
|
HUMIRA (adalimumab)
|
Crohn’s Disease,
Psoriatic Arthritis, Plaque Psoriasis, Rheumatoid Arthritis,
|
Abbott Laboratories
|
|
|
ZEVALIN (ibritumomab
tiuxetan)
|
Non-Hodgkin’s
Lymphoma
|
Biogen Idec
|
|
|
CAMPATH
(alemtuzumab)
|
B-Cell Chronic
Lymphocytic Leukemia
|
Bayer & Genzyme
|
|
|
MYLOTARG
(gemtuzumab)
|
Acute Myeloid
Leukemia
|
Wyeth
|
|
|
HERCEPTIN
(trastuzumab)
|
Breast Cancer
|
Genentech
|
|
|
REMICADE
(infliximab)
|
Crohn’s Disease,
Psoriasis, Rheumatoid Arthritis, Ulcerative Colitis
|
Johnson &
Johnson
|
|
|
SYNAGIS
(palivizumab)
|
Respiratory
Syncytial Virus
|
MedImmune
|
|
|
SIMULECT
(basiliximab)
|
Kidney Transplant
Rejection
|
Novartis
|
|
|
ZENAPAX (daclizumab)
|
Kidney Transplant
Rejection
|
Roche
|
|
|
RITUXAN (rituximab)
|
Non-Hodgkin’s
Lymphoma, Rheumatoid Arthritis
|
Biogen Idec,
Genentech
|
|
|
REOPRO (abciximab)
|
Prevention of Blood
Clots in Angioplasty Patients
|
Eli Lilly
|
|
|
|
Kidney Transplant
Rejection
|
Johnson &
Johnson
|
|
